4//SEC Filing
Daniell Richard 4
Accession 0001193125-25-315938
CIK 0000818686other
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 4:09 PM ET
Size
12.6 KB
Accession
0001193125-25-315938
Insider Transaction Report
Form 4
Daniell Richard
Exec. VP, European Commercial
Transactions
- Exercise/Conversion
Ordinary Shares
2025-12-09$18.61/sh+100,457$1,869,505→ 148,841 total - Exercise/Conversion
Ordinary Shares
2025-12-09$16.99/sh+15,011$255,037→ 163,852 total - Sale
Ordinary Shares
2025-12-09$28.68/sh−115,468$3,311,126→ 48,384 total - Exercise/Conversion
Stock Options (right to buy)
2025-12-09−100,457→ 0 totalExercise: $18.61Exp: 2028-02-09→ Ordinary Shares (100,457 underlying) - Exercise/Conversion
Stock Options (right to buy)
2025-12-09−15,011→ 0 totalExercise: $16.99Exp: 2027-09-18→ Ordinary Shares (15,011 underlying)
Footnotes (4)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.635 to $28.765, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Stock options were granted on February 9, 2018, with 33,485 vested on each of February 9, 2020 and February 9, 2021, and 33,487 vested on February 9, 2022.
- [F4]Stock options were granted on September 18, 2017, with 7,505 vested on September 18, 2018, and 7,506 vested on September 18, 2019.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001726096
Filing Metadata
- Form type
- 4
- Filed
- Dec 10, 7:00 PM ET
- Accepted
- Dec 11, 4:09 PM ET
- Size
- 12.6 KB